Abstract:Accumulating data suggests that the extent of lymphocytic infiltrations into the tumor provides prognostic value in non-small cell lung cancer (NSCLC). However, the factors that influence the status of tumor immune environment remain poorly defined and need investigation. The aim of this study was to assess whether the density of tumor infiltrating lymphocytes (TILs) was related to tumor molecular characteristics in completely resected stage IIIA(N2) lung adenocarcinoma. We retrospectively screened consecutive patients with pathologic stage IIIA(N2) pulmonary adenocarcinomas, who had undergone complete resection in our hospital between 2005 and 2012. Patients who received neoadjuvant chemotherapy and/or radiotherapy were excluded. DNA of EGFR and KRAS was extracted and purified from paraffin-embedded primary lung cancer tissue samples. EGFR (exons 18-21) and KRAS (exons 2, 3) mutation analyses were performed by the DNA sequencing. The density of TILs was evaluated by full-face hematoxylin- and eosin-stained sections from surgical specimens for each case by two specialized pathologists. The degree of lymphocyte infiltration into the tumor was scored as none, low, moderate, or high. Patients were stratified into TIL- (none to low infiltration) or TIL+ (moderate to high infiltration) group based on pathologic evaluation. We investigated the association of densities of TILs with tumor-cell mutation status. Among the 192 eligible patients included, 96 (50%) patients were male and 123 (64%) were never/light ex-smokers, and the median age of all patients was 59 years (range, 22–84 years). There were 84 (43.8%) EGFR mutated and 21 (10.9%) KRAS mutated cases. Among the 84 patients with activating EGFR mutations, there were 30 patients harboring mutations in the exon 19 deletions, 35 patients in the exon 21 L858R mutations, and 1 patient with concurrent exon 19 deletion and L858R mutation. The proportion of patients who had higher density of TILs (TIL+) was lower in the EGFR mutation-positive subgroup (42.9% versus 53.7%, P=0.14) and this difference was significantly observed in the patients with L858R mutation and/or exon 19 deletion subgroup (P=0.026). The proportion of patients who had higher density of TILs (TIL+) was significantly lower in the 66 patients harboring L858R mutation and/or exon 19 deletion (37.9% versus 54.8%, P=0.026). There existed association between the lower density of TILs and activating EGFR mutation status in lung adenocarcinoma, underlying the interactions between cancer cells and their microenvironment. Further studies are warranted to validate these results and clarify the potential molecular mechanisms responsible for regulation of lymphocytic infiltration by activating EGFR pathway.

MA09.10 Paired Specimens Elucidate the Role of Tumor Microenvironment Reprogramming in the Efficacy of Neoadjuvant Chemoimmunotherapy in NSCLC

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Single-Cell RNA Sequencing Reveals Tumor Microenvironment Remodeling after Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen

The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma

Single-cell RNA sequencing reveals microenvironmental infiltration in non-small cell lung cancer with different responses to immunotherapy

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures

Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study

P2.01-057 Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy

Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

Single-cell profiling of immune cells associated with response to neoadjuvant chemoimmunotherapy in IIIA non-small cell lung cancer (NSCLC).

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer

Abstract 625: Remodeling of the tumor microenvironment in esophageal squamous cell carcinoma by neoadjuvant immunochemotherapy and its impact on therapeutic efficacy